Ultra-Rare Tumors: Public-Private Partnership Eyed To Boost Drug Development

 
• By Sue Sutter

US FDA, Foundation for the NIH, and NCI are considering a new PPP aimed at creating a repeatable process for development of drugs to treat ultra-rare cancers where commercial viability is lacking. Stakeholders say industry incentives, IP issues and reimbursement need attention.

Open notebook
The envisioned public-private partnership would take a transparent, open-notebook approach to drug development for ultra-rare tumors. • Source: Shutterstock

More from Rare Diseases

More from Pink Sheet